Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RNS 60

Drug Profile

RNS 60

Alternative Names: Oxygenated saline; RNS60

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Queens University; Revalesio
  • Developer Revalesio; Rush University
  • Class Anti-ischaemics; Antiasthmatics; Antidementias; Antiparkinsonians; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action G protein-coupled receptor modulators; HSP90 heat-shock protein modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Asthma; Multiple sclerosis; Stroke
  • Preclinical Alzheimer's disease; Parkinson's disease; Traumatic brain injuries
  • Discontinued Myocardial infarction

Most Recent Events

  • 07 Feb 2024 Revalesio plans to meet US FDA for phase-III trial for Stroke
  • 07 Feb 2024 Efficacy and adverse events data from phase-II RESCUE trial in Stroke released by Revalesio Corporation
  • 08 Nov 2023 Revalesio Corporation completes phase-II RESCUE trial in Stroke in USA (Injection) (NCT04693715)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top